• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Energy

Mylan Deal Is All That Shell Is Not

The ecstasy and the agony of M&A all in one day.
By JIM CRAMER
Apr 08, 2015 | 12:38 PM EDT
Stocks quotes in this article: MYL, PRGO, RDS.A, ACT, HNZ, KRFT, FDX, UPS, ABBV, PCYC, JNJ

Talk about a right way and a wrong way to do a deal.

Mylan (MYL) proposes a stock-and-cash acquisition for Perrigo (PRGO) and both companies take off as the synergies are obvious and Perrigo's been held back by a couple of one-time-only issues.

Royal Dutch Shell (RDS.A), on the other hand, surveys the world and issues stock and cash for the poorly-performing BG Group, a company in the worst, most glutted part of the oil complex (natural gas), and it gets hammered mercilessly and all the value accrues to the target. Why not? Royal Dutch paid 50% higher than the last sale, even though BG is just performing so terribly. The best hope is that someone comes in and pays even more for BG, relieving shareholders, including my charitable trust, of this ridiculously overpriced agglomeration.

I love this Mylan deal as much as I have loved Perrigo, one of my favorite stocks, as witnessed by the praise I lavished on the company in Get Rich Carefully and on CEO Joe Papa during his myriad visits to "Mad Money." The last Perrigo quarter was marred by a slight flu season and a flood of Chinese vitamin supplements that hurt Perrigo's business. I think both are one-time only and this knock-off drug company will dovetail perfectly with Mylan's generic business.

This Mylan buy smacks of all the right kind of acquisitions we have seen, including the Actavis (ACT) purchase of Allergan, the Heinz (HZN) buy of Kraft (KRFT) and the FedEx (FDX) bid for TNT, the European freight forwarder.

Actavis understood that Allergan has a much underdeveloped Botox program, a pipeline unto itself, and a potential blockbuster eye-care drug for macular degeneration that could be competitive with the entire multi-billion dollar field.

So, the stock of Actavis roars and roars as the synergies become known and the estimates go higher and higher.

Heinz, an international food powerhouse with amazing emerging markets capabilities that is run as lean as can be, takes on Kraft, a bloated domestic company with brands that will thrive overseas, where they are less sensitive to the often seemingly inorganic and unnatural Kraft offerings.

FedEx buys TNT at a much lower price than UPS (UPS) was willing to pay for the Dutch company and comes in when Europe's on the upswing, not on the downdraft. It's brilliant, so both stocks go flying.

Royal Dutch, on the other hand, could have bought so many distressed properties in the U.S. that would have immediately sent its stock skyward. It could have paid much less for BG with the idea that if it couldn't get it, there would be something else in the pipeline besides a company that plays in a field that will be glutted for years to come as the United States floods the world with liquefied natural gas. It's embarrassing and the only thing that saved the Royal Dutch stock, if down 5% is saving it, may be that the company intends to keep paying a very large dividend (although given the price tag and the debt taken on, that promise might prove to be hollow).

This deal reminds me of the desperate gambit by AbbVie (ABBV) to buy Pharmacyclics (PCYC) for $21 billion after the stock is already up about 88% for the year. The natural buyer should have been Johnson & Johnson (JNJ), which already owned 50% of the rights to the best drug of Pharmacyclics, but Abbvie was obviously so concerned about its chief drug Humira coming off patent soon that it just threw its once-valuable stock at Pharmacyclics as what can only be described as an outrageous price.

Mylan for Perrigo, instant wealth creation. Royal Dutch for BG, instant wealth destruction. The ecstasy and the agony all in one day.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long RDS.A,

TAGS: Investing | U.S. Equity | Energy | Healthcare | Stocks

More from Energy

Stuck in a Tough Spot, Chevron Drills Down Strategy

Timothy Collins
Dec 11, 2019 11:55 AM EST

Company takes on challenges to cut risk and raise return, and now the technical picture shows it's primed for a quick $5 to $7 move over the next few weeks.

Enphase Energy Is My 'Stock of the Week'

James "Rev Shark" DePorre
Dec 9, 2019 1:58 PM EST

ENPH has had huge, quick growth.

With Saudi Aramco IPO, Saudis Have Another, Huge Reason to Support Oil's Price

Maleeha Bengali
Dec 9, 2019 8:53 AM EST

And we could be in the middle of the perfect storm for oil markets, where prices can rise aggressively through the first quarter.

Weakness After Protracted Upside Move Causes Discomfort

James "Rev Shark" DePorre
Dec 5, 2019 10:52 AM EST

Some traders seem unsettled by a bit of downside volatility after not experiencing much of it of late.

Insiders at These Companies Didn't Wait for Cyber Monday to Buy

Bret Jensen
Dec 2, 2019 10:00 AM EST

A handful of midstream energy companies and a travel giant have seen insiders purchase their shares in recent weeks.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:55 AM EST BOB LANG

    Strength in Semis and Banks

    Seeing some really good power in the semis today a...
  • 09:16 AM EST CHRIS VERSACE

    Dual Dividend Gift

    Coming up soon on Real Money Pro.
  • 11:02 AM EST BOB LANG

    Added Some Peloton

    This stock is starting to gain some traction, the ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login